Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality
BackgroundChemerin is an extracellular protein with chemotactic activities and its expression is increased in various diseases such as metabolic syndrome and inflammatory conditions. Its role in lung pathology has not yet been extensively studied but both known pro- and anti-inflammatory properties...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.941663/full |
| _version_ | 1798042808953602048 |
|---|---|
| author | Philomène Lavis Philomène Lavis Sofia Morra Carmen Orte Cano Nurhan Albayrak Véronique Corbière Véronique Olislagers Nicolas Dauby Nicolas Dauby Véronique Del Marmol Arnaud Marchant Christine Decaestecker Christine Decaestecker Françoise Mascart Nathalie De Vos Philippe Van de Borne Philippe Van de Borne Isabelle Salmon Isabelle Salmon Isabelle Salmon Myriam Remmelink Marc Parmentier Alessandra Kupper Cardozo Benjamin Bondue Benjamin Bondue |
| author_facet | Philomène Lavis Philomène Lavis Sofia Morra Carmen Orte Cano Nurhan Albayrak Véronique Corbière Véronique Olislagers Nicolas Dauby Nicolas Dauby Véronique Del Marmol Arnaud Marchant Christine Decaestecker Christine Decaestecker Françoise Mascart Nathalie De Vos Philippe Van de Borne Philippe Van de Borne Isabelle Salmon Isabelle Salmon Isabelle Salmon Myriam Remmelink Marc Parmentier Alessandra Kupper Cardozo Benjamin Bondue Benjamin Bondue |
| author_sort | Philomène Lavis |
| collection | DOAJ |
| description | BackgroundChemerin is an extracellular protein with chemotactic activities and its expression is increased in various diseases such as metabolic syndrome and inflammatory conditions. Its role in lung pathology has not yet been extensively studied but both known pro- and anti-inflammatory properties have been observed. The aim of our study was to evaluate the involvement of the chemerin/ChemR23 system in the physiopathology of COVID-19 with a particular focus on its prognostic value.MethodsBlood samples from confirmed COVID-19 patients were collected at day 1, 5 and 14 from admission to Erasme Hospital (Brussels – Belgium). Chemerin concentrations and inflammatory biomarkers were analyzed in the plasma. Blood cells subtypes and their expression of ChemR23 were determined by flow cytometry. The expression of chemerin and ChemR23 was evaluated on lung tissue from autopsied COVID-19 patients by immunohistochemistry (IHC).Results21 healthy controls (HC) and 88 COVID-19 patients, including 40 in intensive care unit (ICU) were included. Plasma chemerin concentration were significantly higher in ICU patients than in HC at all time-points analyzed (p<0.0001). Moreover, they were higher in deceased patients compared to survivors (p<0.05). Logistic univariate regression and multivariate analysis demonstrated that chemerin level at day 14 of admission was an independent risk factor for death. Accordingly, chemerin levels correlated with inflammatory biomarkers such as C-reactive protein and tumor necrosis factor α. Finally, IHC analysis revealed a strong expression of ChemR23 on smooth muscle cells and chemerin on myofibroblasts in advanced acute respiratory distress syndrome (ARDS).DiscussionIncreased plasma chemerin levels are a marker of severity and may predict death of COVID-19 patients. However, multicentric studies are needed, before chemerin can be considered as a biomarker of severity and death used in daily clinical practice. Further studies are also necessary to identify the precise mechanisms of the chemerin/ChemR23 system in ARDS secondary to viral pneumonia. |
| first_indexed | 2024-04-11T22:40:46Z |
| format | Article |
| id | doaj.art-82fabf54a5494ca4abcea9a910de8d4e |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T22:40:46Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-82fabf54a5494ca4abcea9a910de8d4e2022-12-22T03:59:00ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-08-011310.3389/fimmu.2022.941663941663Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortalityPhilomène Lavis0Philomène Lavis1Sofia Morra2Carmen Orte Cano3Nurhan Albayrak4Véronique Corbière5Véronique Olislagers6Nicolas Dauby7Nicolas Dauby8Véronique Del Marmol9Arnaud Marchant10Christine Decaestecker11Christine Decaestecker12Françoise Mascart13Nathalie De Vos14Philippe Van de Borne15Philippe Van de Borne16Isabelle Salmon17Isabelle Salmon18Isabelle Salmon19Myriam Remmelink20Marc Parmentier21Alessandra Kupper Cardozo22Benjamin Bondue23Benjamin Bondue24Department of Pathology, Erasme Hospital, Université libre de Bruxelles, Brussels, BelgiumI.R.I.B.H.M., Université libre de Bruxelles, Brussels, BelgiumDepartment of Cardiology, Erasme Hospital, Université libre de Bruxelles, Brussels, BelgiumDepartment of Dermatology, Erasme Hospital, Université libre de Bruxelles, Brussels, BelgiumLaboratory of Vaccinology and Mucosal Immunity, Université libre de Bruxelles, Brussels, BelgiumLaboratory of Vaccinology and Mucosal Immunity, Université libre de Bruxelles, Brussels, BelgiumInstitute for Medical Immunology, Université libre de Bruxelles, Brussels, BelgiumInstitute for Medical Immunology, Université libre de Bruxelles, Brussels, BelgiumDepartment of Infectious Diseases, C.H.U. Saint-Pierre, Brussels, BelgiumDepartment of Dermatology, Erasme Hospital, Université libre de Bruxelles, Brussels, BelgiumInstitute for Medical Immunology, Université libre de Bruxelles, Brussels, BelgiumDIAPath, Center for Microscopy and Molecular Imaging, Université libre de Bruxelles, Gosselies, BelgiumLaboratory of Image Synthesis and Analysis, Université libre de Bruxelles, Brussels, BelgiumLaboratory of Vaccinology and Mucosal Immunity, Université libre de Bruxelles, Brussels, Belgium0Department of Clinical Chemistry, LHUB-ULB, Université libre de Bruxelles, Brussels, BelgiumDepartment of Cardiology, Erasme Hospital, Université libre de Bruxelles, Brussels, Belgium1Institute for Translational Research in Cardiovascular and Respiratory Sciences, Université libre de Bruxelles, Brussels, BelgiumDepartment of Pathology, Erasme Hospital, Université libre de Bruxelles, Brussels, BelgiumDIAPath, Center for Microscopy and Molecular Imaging, Université libre de Bruxelles, Gosselies, Belgium2Centre Universitaire inter Régional d’expertise en Anatomie Pathologique Hospitalière, Jumet, BelgiumDepartment of Pathology, Erasme Hospital, Université libre de Bruxelles, Brussels, BelgiumI.R.I.B.H.M., Université libre de Bruxelles, Brussels, Belgium3Inflammation and Cell Death Signalling group, Experimental Gastroenterology Laboratory and Endotools, Université libre de Bruxelles, Brussels, BelgiumI.R.I.B.H.M., Université libre de Bruxelles, Brussels, Belgium4Department of Pneumology, Erasme Hospital, Université libre de Bruxelles, Brussels, BelgiumBackgroundChemerin is an extracellular protein with chemotactic activities and its expression is increased in various diseases such as metabolic syndrome and inflammatory conditions. Its role in lung pathology has not yet been extensively studied but both known pro- and anti-inflammatory properties have been observed. The aim of our study was to evaluate the involvement of the chemerin/ChemR23 system in the physiopathology of COVID-19 with a particular focus on its prognostic value.MethodsBlood samples from confirmed COVID-19 patients were collected at day 1, 5 and 14 from admission to Erasme Hospital (Brussels – Belgium). Chemerin concentrations and inflammatory biomarkers were analyzed in the plasma. Blood cells subtypes and their expression of ChemR23 were determined by flow cytometry. The expression of chemerin and ChemR23 was evaluated on lung tissue from autopsied COVID-19 patients by immunohistochemistry (IHC).Results21 healthy controls (HC) and 88 COVID-19 patients, including 40 in intensive care unit (ICU) were included. Plasma chemerin concentration were significantly higher in ICU patients than in HC at all time-points analyzed (p<0.0001). Moreover, they were higher in deceased patients compared to survivors (p<0.05). Logistic univariate regression and multivariate analysis demonstrated that chemerin level at day 14 of admission was an independent risk factor for death. Accordingly, chemerin levels correlated with inflammatory biomarkers such as C-reactive protein and tumor necrosis factor α. Finally, IHC analysis revealed a strong expression of ChemR23 on smooth muscle cells and chemerin on myofibroblasts in advanced acute respiratory distress syndrome (ARDS).DiscussionIncreased plasma chemerin levels are a marker of severity and may predict death of COVID-19 patients. However, multicentric studies are needed, before chemerin can be considered as a biomarker of severity and death used in daily clinical practice. Further studies are also necessary to identify the precise mechanisms of the chemerin/ChemR23 system in ARDS secondary to viral pneumonia.https://www.frontiersin.org/articles/10.3389/fimmu.2022.941663/fullCOVID-19chemerinChemR23CMKLR1survivalARDS |
| spellingShingle | Philomène Lavis Philomène Lavis Sofia Morra Carmen Orte Cano Nurhan Albayrak Véronique Corbière Véronique Olislagers Nicolas Dauby Nicolas Dauby Véronique Del Marmol Arnaud Marchant Christine Decaestecker Christine Decaestecker Françoise Mascart Nathalie De Vos Philippe Van de Borne Philippe Van de Borne Isabelle Salmon Isabelle Salmon Isabelle Salmon Myriam Remmelink Marc Parmentier Alessandra Kupper Cardozo Benjamin Bondue Benjamin Bondue Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality Frontiers in Immunology COVID-19 chemerin ChemR23 CMKLR1 survival ARDS |
| title | Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality |
| title_full | Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality |
| title_fullStr | Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality |
| title_full_unstemmed | Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality |
| title_short | Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality |
| title_sort | chemerin plasma levels are increased in covid 19 patients and are an independent risk factor of mortality |
| topic | COVID-19 chemerin ChemR23 CMKLR1 survival ARDS |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.941663/full |
| work_keys_str_mv | AT philomenelavis chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT philomenelavis chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT sofiamorra chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT carmenortecano chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT nurhanalbayrak chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT veroniquecorbiere chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT veroniqueolislagers chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT nicolasdauby chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT nicolasdauby chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT veroniquedelmarmol chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT arnaudmarchant chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT christinedecaestecker chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT christinedecaestecker chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT francoisemascart chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT nathaliedevos chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT philippevandeborne chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT philippevandeborne chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT isabellesalmon chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT isabellesalmon chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT isabellesalmon chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT myriamremmelink chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT marcparmentier chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT alessandrakuppercardozo chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT benjaminbondue chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality AT benjaminbondue chemerinplasmalevelsareincreasedincovid19patientsandareanindependentriskfactorofmortality |